IOVANCE BIOTHERAPEUTICS, INC.
In the published model solve dated 2026-Q2, anchored at $4.32, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is priced for today's economics sustained for ~17.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed August 7, 2026 from SEC EDGAR filings.
• Amtagvi, described in the company's own filings as ⟦"the first one-time, individualized T cell therapy approved for a solid tumor cancer"⟧, produced $150.9 million of revenue in the first half of 2026 against $97.6 million a year earlier, and it is now doing the work of an entire company. • The loss is shrinking fast but is still large: the June quarter's operating loss was $51.9 million against $113.8 million a year earlier, and the funding for that gap comes from selling stock, with shares o
Is IOVA overvalued? See what's priced in →
272 institutional managers reported holding IOVA in 13F filings for the quarter ended 2026-03-31. Together they hold about 64% of the company; the top 10 hold 40%. 56 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 103.5M shares were sold short as of the 2026-06-15 count, about 25% of shares outstanding (7.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
IOVA's share count grew 151.3% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at IOVA over the trailing three years: 2023: 2 buys totaling $26.56M; 2024: 3 buys totaling $48.33M; 2025: 3 buys totaling $107k. 8 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
IOVA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +7.8% | -48.5% |
| 2023-11-08 | -3.5% | +124.2% |
| 2024-02-29 | -8.9% | -19.0% |
| 2024-05-10 | -18.1% | -20.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
IOVA's latest 8-K filings: 2026-08-06 (items 8.01, 9.01); 2026-08-06 (items 2.02, 9.01); 2026-07-02 (items 8.01, 9.01); 2026-06-10 (items 5.07, 8.01, 9.01); 2026-05-07 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 7, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.